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Abstract 22 
Background: MUC4 is a membrane-bound mucin that promotes carcinogenetic progression 23 
and is often proposed as a promising biomarker for various carcinomas. In this manuscript, 24 
we analyzed large scale genomic datasets in order to evaluate MUC4 expression, identify 25 
genes that are correlated with MUC4 and propose new signatures as a prognostic marker of 26 
epithelial cancers. 27 
Methods Using cBioportal or SurvExpress tools, we studied MUC4 expression in large-scale 28 
genomic public datasets of human cancer (The cancer genome atlas, TCGA) and Cancer 29 
Cell Line Encyclopedia (CCLE). 30 
Results: We identified 187 co-expressed genes for which the expression is correlated with 31 
MUC4 expression. Gene ontology analysis showed they are notably involved in cell 32 
adhesion, cell-cell junctions, glycosylation and cell signaling. In addition, we showed that 33 
MUC4 expression is correlated with MUC16 and MUC20, two other membrane-bound 34 
mucins. We showed that MUC4 expression is associated with a poorer overall survival in 35 
TCGA cancers with different localizations including pancreatic cancer, bladder cancer, colon 36 
cancer, lung adenocarcinoma, lung squamous adenocarcinoma, skin cancer and stomach 37 
cancer. We showed that the combination of MUC4, MUC16 and MUC20 signature is 38 
associated with statistically significant reduced overall survival and increased hazard ratio in 39 
pancreatic, colon and stomach cancer. 40 
Conclusions: Altogether, this study provides the link between (i) MUC4 expression and 41 
clinical outcome in cancer and (ii) MUC4 expression and correlated genes involved in cell 42 
adhesion, cell-cell junctions, glycosylation and cell signaling. We propose the 43 
MUC4/MUC16/MUC20high signature as a marker of poor prognostic for pancreatic, colon and 44 
stomach cancers. 45 
Keywords: MUC4, TCGA, CCLE, patient survival, biomarker 46 
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Abbreviations: 48 
 49 
AUROC: Area Under Receiving Operator Characteristic 50 
CCLE: Cancer Cell Line Encyclopedia 51 
HR: Hazard ratio 52 
PDAC: Pancreatic Ductal AdenoCarcinoma 53 
ROC: Receiving operator characteristic 54 
TCGA: The cancer genome atlas 55 
 56 
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Background 58 
 59 
The cancer genome atlas (TCGA) was developed by National Cancer Institute (NCI) and 60 
National Human Genome Research Institute (NHGRI) in order to provide comprehensive 61 
mapping of the key genomic changes that occur during carcinogenesis. Datasets of more 62 
than 11,000 patients of 33 different types of tumors are publically available. In parallel, 63 
Cancer Cell Line Encyclopedia (CCLE), a large-scale genomic dataset of human cancer cell 64 
lines, was generated by the Broad Institute and Novartis in order to reflect the genomic 65 
diversity of human cancers and provide complete preclinical datasets for mutation, copy 66 
number variation and mRNA expression studies [1]. In order to analyse this kind of large 67 
scale datasets, several useful online tools have been created. cBioportal is an open-access 68 
database analysis tool developed at the Memorial Sloan-Kettering Cancer Centre (MSKCC) 69 
to analyze large-scale cancer genomics data sets [2, 3]. SurvExpress is another online tool 70 
for biomarker validation using 225 datasets available and therefore provide key information 71 
linking gene expression and the impact on cancer outcome [4].  72 
Mucins are large high molecular weight glycoproteins that are classified in two sub groups: (i) 73 
the secreted mucins that are responsible of rheologic properties of mucus and (ii) the 74 
membrane-bound mucins that include MUC4, MUC16 and MUC20 [5, 6]. MUC4 was first 75 
discovered in our laboratory 25 years ago from a tracheobronchial cDNA library [7]. MUC4 is 76 
characterized by a long hyper-glycosylated extracellular domain, Epidermal Growth Factor 77 
(EGF)-like domains, a hydrophobic transmembrane domain, and a short cytoplasmic tail. 78 
MUC4 also contains NIDO, AMOP and vWF-D domains [8]. A direct interaction between 79 
MUC4 and its membrane partner, the oncogenic receptor ErbB2, alters downstream 80 
signaling pathways [9]. MUC4 is expressed at the surface of epithelial cells from 81 
gastrointestinal and respiratory tracts [10] and has been studied in various cancers where it 82 
is generally overexpressed and described as an oncomucin and has been proposed as an 83 
attractive prognostic tumor biomarker. Its biological role has been mainly evaluated in 84 
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pancreatic, ovarian, esophagus and lung cancers [9, 11-14]. Other membrane-bound mucins 85 
MUC16 and MUC20 share some functional features but evolved from distinct ancestors [15]. 86 
MUC20 gene is located on the chromosomic region 3q29 close to MUC4. MUC16 also 87 
known as the CA125 antigen is a routinely used serum marker for the diagnosis of ovarian 88 
cancer [16]. Both mucins favor tumor aggressiveness and are associated with poor overall 89 
survival and could be proposed as prognosis factors [16-18]. 90 
In this manuscript, we have used the online tools cBioportal, DAVID6.8 and SurvExpress in 91 
order to (i) evaluate MUC4 expression in various carcinomas, (ii) identify genes that are 92 
correlated with MUC4 and evaluate their roles and (iii) propose MUC4/MUC16/MUC20 93 
combination as a prognostic marker of pancreatic, colon and stomach cancers.  94 
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Material and methods 96 
 97 
Expression analysis from public datasets 98 
MUC4 z-score expressions were extracted from databases available at cBioPortal for Cancer 99 
Genomics [2, 3]. This portal stores expression data and clinical attributes. The z-score for 100 
MUC4 mRNA expression is determined for each sample by comparing mRNA expression to 101 
the distribution in a reference population harboring typical expression for the gene. The query 102 
“MUC4” was realized in CCLE (881 samples, Broad Institute, Novartis Institutes for 103 
Biomedical Research) [1] and in all TCGA datasets available (13 489 human samples, TCGA 104 
Research Network (http://cancergenome.nih.gov/)). The mRNA expression from selected 105 
data was plotted in relation to the clinical attribute (tumor type and histology) in each sample. 106 
MUC4 expression was analyzed in normal tissues by using the Genome Tissue Expression 107 
(GTEX) tool [19, 20]. Data were extracted from GTEX portal on 06/29/17 (dbGaP accession 108 
phs000424.v6.p1) using the 4585 Entrez gene ID.  109 
 110 
DAVID6.8 identification and gene ontology of genes correlated with MUC4 111 
We established a list of 187 genes that are correlated with MUC4 expression in CCLE 112 
dataset out of 16208 genes analyzed with cBioportal tool on co-expression tab. These genes 113 
harbor a correlation with both Pearson’s and Spearman’s higher than 0.3 or lower than -0.3. 114 
Functional annotation and ontology clustering of the complete list of genes were performed 115 
using David Functional Annotation Tool (https://david.ncifcrf.gov/) and Homo sapiens 116 
background [21, 22]. Enrichment scores of ontology clusters are provided by the online tool. 117 
Interaction of proteins correlated with MUC4 was determined using String 10 tool 118 
(https://string-db.org/) [23]. Edges represent protein-protein associations such as known 119 
interactions (from curated databases or experimentally determined), predicted interactions 120 
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(from gene neighborhood, gene fusion or co-occurrence), text-mining, co-expression or 121 
protein homology. The network was divided in 3 clusters based on k-means clustering. 122 
 123 
Methylation and copy number analysis 124 
Using https://portals.broadinstitute.org/ccle, we extracted mRNA expression of MUC4, 125 
methylation score (Reduced Representation Bisulfite Sequencing: RRBS) and copy number 126 
variations of the genes of interest. The mRNA expression of MUC4 was plotted in relation to 127 
log2 copy number or RRBS score. 128 
 129 
SurvExpress survival analysis 130 
Survival analysis was performed using the SurvExpress online tool available in 131 
bioinformatica.mty.itesm.mx/SurvExpress (Aguire Gamboa PLos One 2013). We used the 132 
optimized algorithm that generates risk group by sorting prognostic index (higher value of 133 
MUC4 for higher risk) and split the two cohorts where the p-value is minimal. Hazard ratio 134 
[95% confidence interval (CI)] was also evaluated. The tool also provided a box plot of genes 135 
expression and the corresponding p value testing the differences. 136 
 137 
Gene Expression Omnibus microarray 138 
GSE28735 and GSE16515 pancreatic cancer microarrays were analysed from the NCBI 139 
Gene Expression Omnibus (GEO) database (http://www.ncbi.nml.nih.gov/geo/). GSE28735 140 
is a dataset containing 45 normal pancreas (adjacent non tumoral, ANT) and 45 tumor (T) 141 
tissues from PDAC cases. GSE16515 contains 52 samples (16 had both tumor and normal 142 
expression data, and 20 only had tumor data. Data were analysed using GEO2R software. 143 
The dataset GSE28735 used Affymetrix GeneChip Human Gene 1.0 ST array. The dataset 144 
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GSE16515 used the Affymetrix Human Genome U133 Plus 2.0 Array. GSE13507 contains 145 
165 bladder cancer and 58 ANT samples. GSE30219 contains 14 normal lung, 85 146 
adenocarcinomas and 61 squamous cancer samples. GSE40967 contains 566 colorectal 147 
cancers and 19 normal mucosae. GSE27342 contains 80 tumors and 80 paired ANT tissues. 148 
GSE4587 contains 2 normal, 2 melanomas and 2 metastatic melanomas. GSE14407 149 
contains 12 ovarian adenocarcinomas and 12 normal ovary samples. 150 
 151 
Statistical analysis 152 
For MUC4 expression analysis, paired and unpaired t test statistical analyses were 153 
performed using the Graphpad Prism 6.0 software (Graphpad softwares Inc., La Jolla, CA, 154 
USA). P<0.05 was considered as statistically significant. Receiving operator characteristic 155 
(ROC) curves and areas under ROC (AUROC) were evaluated by comparing tumor and ANT 156 
values. cBioportal provided Pearson and Spearman tests were performed to analyze 157 
correlation of other genes, RRBS score and log2 copy number with MUC4 expression. 158 
DAVID tool provided p value of each ontology enrichment score. SurvExpress tool provided 159 
statistical analysis of hazard ratio and overall survival. A Log rank testing evaluated the 160 
equality of survival curves between the high and low risk groups.  161 
 162 
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Results 164 
 165 
MUC4 expression analysis in databases 166 
MUC4 expression was analyzed from databases available at cBioPortal for Cancer 167 
Genomics [2, 3]. We queried for MUC4 mRNA expression in the 881 samples from CCLE [1] 168 
(Figure 1). The oncoprint showed that MUC4 was altered in 195 samples out of 881 (22%). 169 
188 were amplification (n=120) or mRNA upregulation (n=88) (Supplemental Figure 1). 170 
Results were sorted depending on the tumor type. We mainly observed an important z-score 171 
expression of MUC4 in carcinoma samples (n= 538 samples, p=0.001) (Figure 2A). MUC4 172 
Expression scores were subsequently sorted depending of the organ (Figure 2B). As 173 
expected, pancreatic cancer cell lines harbor the highest MUC4 expression (n=35, z-174 
score=2.166, p=0,0006 against theoretical control median=0). Other cell lines from different 175 
tissues (lung NSC, esophagus, bile duct, stomach, upperdigestive, colorectal, ovary, and 176 
urinary tract) showed statistically significant alteration. We also performed a similar analysis 177 
on 13 489 human samples retrieved from TCGA by using the cBioportal platform. An 178 
important MUC4 expression z-score was observed in bladder urothelial carcinoma, cervical 179 
squamous cell carcinoma/endocervical adenocarcinoma, colorectal carcinoma, esophageal 180 
carcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous 181 
cell carcinoma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, prostate 182 
adenocarcinoma, stomach adenocarcinoma and uterine corpus endometrial carcinoma 183 
(Figure 3). Expression of MUC4 in normal tissues was analyzed using the GTEX project tool, 184 
MUC4 was expressed in lung, testis, small intestine, terminal, ileum, prostate, vagina, minor 185 
salivary gland and esophagus mucosa and transverse colon (supplemental figure2). 186 
Altogether, this shows that MUC4 high expression is observed in carcinoma and notably in 187 
pancreatic cancer. 188 
 189 
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MUC4 co-regulated genes 190 
Using the co-expression tool on expression data extracted from the 881 samples of CCLE 191 
[1], we obtained a list of genes that are co-expressed with MUC4. Genes that harbor a 192 
correlation with both Pearson’s and Spearman’s higher than 0.3 or lower than -0.3 were 193 
selected. 187 genes are positively (n=178) or negatively (n=9) correlated with MUC4 194 
expression. The better correlated genes were Adhesion G Protein-Coupled Receptor F1 195 
(ADGRF1, Pearson’s correlation=0.56) and Lipocalin2 (LCN2, Pearson’s correlation=0.54) 196 
(table 1). We also observed that expression of other membrane bound mucins MUC16 and 197 
MUC20 are positively correlated with MUC4. Correlation between MUC16 and MUC20 was 198 
also observed (not shown). Only few genes were negatively correlated such as ZEB1 199 
transcription factor or ST3 Beta-Galactoside Alpha-2,3-Sialyltransferase 2 (ST3GAL2) (table 200 
2). 201 
Functional Annotation of the complete list of genes and ontology clustering were performed 202 
using David Functional Annotation Tool. The gene clustering analysis is presented in table 3. 203 
The complete gene ontologies that are statistically significant are provided in supplemental 204 
table 1. We observed the highest enrichment scores in gene clusters involved in cell 205 
adhesion (7.08) and tight junction (5.44) (table 3). Notably, we observed the correlation of 206 
expression of MUC4 with genes encoding integrins (ITGB4 and ITGB6) and cadherin-type 207 
proteins such as CDH1, CDH3, Desmocollin 2 (DSC2). A strong enrichment of 91 208 
transmembrane proteins was observed including EPH Receptor A1 (EPHA1), Epithelial cell 209 
adhesion molecule (EPCAM), Carcinoembryonic Antigen Related Cell Adhesion Molecule-5 210 
and -6 (CEACAM5 and CEACAM6), C-X-C motif chemokine ligand 16 (CXCL16) and 211 
ATPase Secretory Pathway Ca2+ Transporting 2 (ATP2C2). As MUC4 is a glycoprotein, it is 212 
interesting to also note the correlated expression of enzymes involved in different steps of 213 
glycosylation such sialyltransferases (ST3GAL2, ST6GALNAC1), beta-1,3-N-214 
acetylglucosaminyltransferases (B3GNT5, B3GNT3), fucosyltransferases (FUT3, FUT2), and 215 
UDP-GalNAc transferase (GALNT3). MUC4 was also associated with genes associated with 216 
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cell signaling containing SH2 domain (Cbl proto-oncogene C (CBLC), signal transducing 217 
adaptor family member 2 (STAP2), dual adaptor of phosphotyrosine and 3-phosphoinositides 218 
1 (DAPP1), SH2 domain containing 3A (SH2D3A), protein tyrosine kinase 6 (PTK6), growth 219 
factor receptor bound protein 7 (GRB7), fyn related Src family tyrosine kinase (FRK), tensin 4 220 
(TNS4)) or SH3 domains (MET transcriptional regulator (MACC1), Rho GTPase activating 221 
protein 27 (ARHGAP27), tight junction protein 2 (TJP2), Rho guanine nucleotide exchange 222 
factor-5 and -16 (ARHGEF5, ARHGEF16), protein tyrosine kinase 6 (PTK6), EPS8 like 1 223 
(EPS8L1), tight junction protein 3 (TJP3) and FRK). Finally, several genes encoding proteins 224 
with a SEA domain (ADGRF1, ST14, MUC16) were correlated with MUC4 expression. 225 
Additionally, we analyzed protein-protein interactions of differentially expressed proteins with 226 
MUC4 with the String 10 tool. We showed that MUC4 is directly related with CEACAM5, 227 
CEACAM6, MUC16, MUC20 and glycosylation enzymes (ST3GAL2, B3GNT3, B3GNT5 and 228 
GALNT3) (Supplemental Figure 3). Altogether, we have identified genes with expression 229 
correlated with MUC4 involved notably in cell adhesion, cell-cell junctions, glycosylation and 230 
cell signaling. In order to understand the association between the observed aberrant 231 
expression of MUC4 and other molecular events, we explored the correlation between MUC4 232 
expression in CCLE and DNA methylation (RRBS) of the top genes correlated with MUC4. 233 
We observed that MUC4 expression is negatively correlated with the methylation score of 16 234 
out of 20 of the top genes (LCN2, MUC20, STEAP4, WFDC2, GJB3, SH2D3A, RNF39, 235 
PRSS22, HS3ST1, GPR87, TACST2, FAM83A, LAMC2, B3GNT3, CLDN7) (Figure 4) 236 
suggesting that the association of MUC4 and the correlated genes could be mediated by 237 
methylation regulation. Only ADGRF1 RBBS is not correlated with MUC4 mRNA level. 238 
MUC16, SCEL and C1ORF116 scores were not available. Additionally we also evaluated the 239 
copy number variation association of the top genes with MUC4 expression. We only 240 
observed a weak amplification of MUC20 copy number (Pearson’s correlation = 0.13) and a 241 
weak deletion of MUC16 copy number (Pearson’s correlation = -0.14) suggesting that the 242 
relationship between MUC4 expression and copy number variation of top genes is unlikely 243 
(Supplemental Figure 4). 244 
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 245 
MUC4 and patient survival 246 
To establish a correlation between MUC4 expression and patient survival, we have 247 
compared survival analysis and hazard ratio in population designated as MUC4 high risk and 248 
low risk in every organ from TCGA datasets (table 4). We have used SurvExpress optimized 249 
algorithm that generates risk group by sorting prognostic index (higher value of MUC4 for 250 
higher risk). The algorithm splits the population where the p-value testing the difference of 251 
MUC4 expression is minimal [4]. Pancreatic cancer presented the most important hazard 252 
ratio for MUC4 (HR= 3.94 [CI, 1.81-8.61] p=0.0005756) (Figure 5A). MUC4 high risk was 253 
also significantly associated with survival in bladder cancer (HR= 1.48), colon cancer (HR= 254 
2.1), lung adenocarcinoma (HR= 1.7), lung squamous carcinoma (HR= 1.69), ovarian cancer 255 
(HR= 1.33), skin cancer (HR= 1.87) and stomach cancer (HR= 1.58) (Figure 5A). Acute 256 
myeloid leukemia (HR= 1.59) and liver cancer (HR= 1.4) almost reach statistical significance. 257 
Other datasets did not show any statistically significant differences. 258 
A significant reduction in patient’s survival was observed in bladder cancer (p=0.01135), 259 
colon cancer (p=.00891), lung adenocarcinoma (p=0.008187), lung squamous carcinoma 260 
(p=0.03586), ovarian cancer (p=0.0186), pancreatic cancer (p=0.000219), skin cancer 261 
(p=0.02384) and stomach cancer (p=0.04751) as illustrated in Kaplan Meier curves (Figure 262 
5B). Strikingly, pancreatic median survival was 593 days in MUC4high cohort (n=149) whereas 263 
the 50% survival was not reached in MUC4low cohort (n=27). In lung squamous carcinoma, 264 
the median survival of MUC4high cohort (n=116) was 1067 days whereas MUC4low cohort 265 
(n=59) presented a 2170 days median survival. It is interesting to note that the algorithm 266 
splits the population in two parts that were characterized as the most different regarding 267 
MUC4 expression. Therefore, there are a modest number of MUC4low PDAC or lung 268 
adenocarcinoma patients and a low number of MUC4high colon or stomach cancer patients. A 269 
similar survival analysis was performed on pancreatic cancer by dividing the patient 270 
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population in two equal parts (88 vs 88), MUC4high harbored a decreased survival that was 271 
close to statistical significance (p=0.06784) (not shown). Therefore, MUC4 expression is 272 
associated with a poorer overall survival in different cancers including pancreatic cancer. 273 
We also compared the survival and hazard ratio, in the same cancers whose survival is 274 
associated with MUC4 (bladder cancer, colon cancer, lung adenocarcinoma, lung squamous 275 
carcinoma, ovarian cancer, pancreatic cancer, skin cancer and stomach cancer), according 276 
to gene signatures corresponding to the five first gene ontology term from supplemental table 277 
1 (GO 0031424: keratinization, GO 0007155: cell adhesion, GO 0019897: extrinsic 278 
component of plasma membrane, GO 0016323 : basolateral plasma membrane and GO 279 
0016324: apical plasma membrane) (Figure 6A, supplemental table 2). These gene 280 
signatures were all significantly associated with survival in the TCGA dataset tested. The 281 
“keratinization” (GO 0031424) and “cell adhesion” (GO 0007155) signature are associated 282 
with HR comprised between 1.65 and 3.76 and between 2.15 and 3.23, respectively. The GO 283 
0019897 signature is associated with weaker HR (1.55-2.30). “basolateral” (GO 0016323) 284 
and “apical plasma membrane” (GO 0016324) signatures harbors more increased HR (2.21-285 
4.5 and 1.77-4.42, respectively) in these datasets. 286 
We performed a similar analysis according to the top genes (ADGRF1, LCN2, MUC20, 287 
C1ORF116, SCEL, STEAP4) that harbored Pearson’s correlation with MUC4 superior to 0.5 288 
(Figure 6B, supplemental table 3). This signature is associated with survival in all TCGA 289 
dataset tested (HR comprised between 1.91 and 8.77). Notably, pancreatic cancer harbored 290 
the strongest association with survival according to this signature (HR=8.77 [CI, 2.15-35.83]). 291 
Overall, these bigger signatures harbored higher hazard ratio compared to MUC4 alone. 292 
 293 
MUC4, MUC16 and MUC20 signature in cancer 294 
Mucins have been proposed as potential biomarkers for carcinoma. Notably, previous work 295 
suggested that combination of mucins expression may be useful for early detection and 296 
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evaluation of malignancy of pancreatobiliary neoplasms [24]. Moreover, MUC16/CA125 297 
antigen is an already routinely used serum marker for the diagnosis of ovarian cancer [16]. 298 
Therefore, we decided to intentionally focus on the two other membrane bound mucins 299 
MUC16 and MUC20 that were correlated with expression of MUC4. We analyzed the survival 300 
curves of the high risk group (MUC4/MUC16/MUC20high, n= 159) and low risk group 301 
(MUC4/MUC16/MUC20low, n=17) from the pancreas TCGA dataset. The 302 
MUC4/MUC16/MUC20high risk group was associated with an increased hazard ratio (HR=6.5 303 
[2.04-20.78], p=0.001582) and a shorter overall survival (p=0.0003088) (Figure 7A). Median 304 
survival was similar as in MUC4high cohort (593 days). The MUC4/MUC16/MUC20high group 305 
harbored a statistically significant increase of MUC4, MUC16 and MUC20 expression (Figure 306 
7B). We also analyzed overall survival in every other PDAC database available in 307 
Surexpress. We show that MUC4high group was associated with a statistically significant 308 
reduced overall survival and increased hazard ratio in both ICGC and Stratford (GSE21501) 309 
cohorts (Figure 7C). In Zhang cohort (GSE28735), MUC4high group was associated with a 310 
reduced overall survival that was close to statistical significance (p=0.08971). In other 311 
organs, the MUC4/MUC16/MUC20high group was associated with an increased hazard ratio 312 
and reduced overall survival in bladder cancer, colon cancer, lung adenocarcinoma, lung 313 
squamous adenocarcinoma, skin cancer, stomach cancer (supplemental figure 5A). Notably, 314 
the MUC4/MUC16/MUC20high group in colon cancer (HR=2.26 [1.51-3.4]) showed a median 315 
survival of 1741 days whereas the low risk group did not reach the 50% survival. Similarly, 316 
the MUC4/MUC16/MUC20high group in stomach cancer showed a median survival of 762 317 
days whereas the low risk had a median survival of 1811 days. No significant difference was 318 
observed for ovarian cancer (p=0.2081). Moreover, a reduced overall survival was observed 319 
in liver cancer (p=0.04789) and acute myeloid leukemia (AML) (p=0.02577) (supplemental 320 
Figure 5B) in which we did not show any statistical difference when sorting the patients for 321 
MUC4 alone. Overall, we observed that MUC4/MUC16/MUC20 signature harbored an 322 
increased hazard ratio compared with MUC4 alone for pancreatic cancer and to a lower 323 
extent in bladder cancer, colon cancer, lung squamous cancer and stomach cancer. 324 
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We analyzed MUC4, MUC16 and MUC20 expression in pancreatic tumor (T) and paired 325 
adjacent non tumoral tissues (ANT) from GSE28735 (Figure 6) and GSE16515 (not shown) 326 
datasets [25, 26]. We confirmed MUC4 overexpression in tumor tissues (p<0.0001). MUC16 327 
and MUC20 mRNA level were also increased (p<0.0001 and p=0.0062) in tumor samples 328 
(Figure 8A). As previously observed in CCLE dataset, MUC4 expression was correlated with 329 
MUC16 (p=0.0006) and MUC20 (p=0.0621) in GSE28735 (Supplemental Figure 6). We also 330 
analyzed MUC4, MUC16 and MUC20 expression in datasets of other cancers (supplemental 331 
Figure 7). MUC4 expression is increased in bladder cancer vs ANT (GSE13507, p<0.01). 332 
MUC20 is increased in lung adenocarcinoma vs normal samples (GSE30219, p<0.05). 333 
MUC4 and MUC20 expression is increased in colorectal cancer vs normal mucosae 334 
(GSE40967, p<0.01). MUC16 and MUC20 relative expression is increased in ovarian 335 
adenocarcinoma (GSE14407, p<0.01 and p<0.05 respectively). ROC curves of MUC4, 336 
MUC16, MUC20 and MUC4+MUC16+MUC20 combination were established using 337 
GSE28735 dataset. The combination of MUC4+MUC16+MUC20 produced a high specificity 338 
of 97.78% (88.23-99.94) and a mild sensitivity of 55.56% (40-70.36) (likelihood ratio = 25) 339 
(Figure 8B). Similar results were obtained for GSE16515 with 93.75% specificity and 69.44% 340 
sensitivity (LR+=11.11) (not shown). MUC16 AUROC was similar to that of 341 
MUC4+MUC16+MUC20 in GSE28735 dataset but harbors a lower specificity/sensitivity in 342 
GSE16515. 343 
Altogether, this suggests that MUC4/MUC16/MUC20high signature would be useful in 344 
stratification of patients with worst prognosis in several carcinoma and notably pancreatic, 345 
stomach and colon cancers. 346 
347 
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Discussion 348 
 349 
The TCGA and the CCLE have provided a tremendous amount of publicly available data 350 
combining gene expression information related to clinical outcome. Web-based tools allow 351 
the scientific community to perform powerful large scale genomic analysis and propose new 352 
biomarkers or new therapeutic targets. In the present report, we analyzed MUC4 expression 353 
systematically in all organs and confirmed its aberrant expression in associated carcinoma. 354 
We identified 187 genes for which the expression is correlated with MUC4 expression. These 355 
genes are involved in cell adhesion, cell-cell junctions, glycosylation and cell signaling. 356 
MUC4 was also correlated with MUC16 and MUC20 membrane bound mucins. This 357 
combination is associated with a poorer overall survival in different cancers including 358 
pancreatic, colon and stomach cancers suggesting MUC4/MUC16/MUC20 as a poor 359 
prognostic signature for these cancers. 360 
Previous works have showed that MUC4 is altered in normal, premalignant and malignant 361 
epithelia of the digestive tract [27]. The mechanisms underlying this alteration of expression 362 
are diverse and involve regulators such as growth factors, cytokines, demethylation of 363 
promoters and miRNA [28-32]. In the present manuscript we also observe that MUC4 gene is 364 
amplified in 13% of cancer cell lines. We also found a mild correlation between alteration of 365 
MUC4 copy number and MUC4 expression suggesting that gene amplification could also 366 
mediate this MUC4 aberrant expression. This kind of regulation is scarcely described in the 367 
literature. In TCGA, We confirmed that MUC4 expression was observed mainly in human 368 
carcinomas including bladder, cervix, head and neck, lung, ovarian, pancreatic, prostate, 369 
stomach carcinomas. For most of these organs, MUC4 high expression was associated with 370 
a poorer overall survival. MUC4 is one of the most differentially expressed genes in 371 
pancreatic cancer that are thought to be potential clinical targets [33]. Recently, a meta-372 
analysis based on 1900 patients from 18 studies showed that MUC4 overexpression was 373 
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associated with tumor stage, tumor invasion and lymph node metastasis [34]. A worse 374 
overall survival was observed in MUC4-overexpressing patients with biliary tract carcinoma 375 
(HR 2.41), pancreatic cancer (HR 2.01), and colorectal cancer (HR 1.73). Using the TCGA 376 
cohorts, we extended this finding on lung adenocarcinoma, lung squamous carcinoma, 377 
ovarian cancer, skin cancer and stomach cancer. The authors noted that a limit of this meta-378 
analysis was insufficient statistical power of some eligible studies. The large scale genomic 379 
approach of TCGA helps us to overcome this limitation. Based on available TCGA datasets, 380 
mucin mutation map was generated by cBioPortal Mutation Mapper [35]. MUC4 mutations 381 
were notably observed in Kidney Clear Cell Renal Carcinoma (20-45%) and were correlated 382 
with survival outcomes. Rare mutations were described in the main overexpressing model 383 
that is pancreatic cancer. Because of the very large size of MUC4 gene, probability of 384 
acquiring mutation could be increased. MUC4 belongs to the most mutated genes upon 385 
stress exposure such as nicotine treatment or aging [36, 37]. The enrichment of mutation of 386 
MUC4 could be related with the fact that the first risk factor of kidney cancer is smoking [38] 387 
and that kidney cancer diagnosis is occurring at elder ages (65 years) [39]. Pancreatic 388 
cancer shares these characteristics but harbors a very rare mutation occurrence (3%) 389 
suggesting that aging could be specific of cancers such as kidney or lung and that 390 
overexpression is more important for other cancers. So far, functional consequences of 391 
MUC4 mutation remain to be elucidated. 392 
We and others have investigated MUC4 biological roles in various cancers such as 393 
pancreatic, ovarian, esophagus and lung cancers. MUC4 was shown to promote 394 
aggressiveness of tumors as it induces proliferation, migration, invasion, EMT, cell stemness 395 
and chemoresistance [9, 11-14]. In the present work, we showed that MUC4 expression was 396 
correlated with genes, such as integrins cadherin-type proteins, involved in cell adhesion and 397 
cell-cell junctions. As a membrane-bound mucin, MUC4 is thought to act on cell-cell and cell-398 
MEC interaction. Because of its huge extracellular domain that profoundly modifies steric 399 
hindrance, MUC4 may alter migration, invasion and adherence properties [40]. Rat 400 
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homologue of MUC4, sialomucin complex (SMC), overexpression leads to suppression of 401 
cell adhesion [41]. Notably, MUC4 overexpression disrupts the adherens junctions and leads 402 
to partial delocalization of E-cadherin to the apical surface of the cell causing loss of cell 403 
polarity [42]. Moreover, interactions between MUC4 glycans and galectin-3 were shown to 404 
also mediate docking of circulating tumor cells to the surface of endothelial cells [43]. The 405 
alteration of cell adhesion induced by MUC4 is one of the first steps toward the metastatic 406 
process. MUC4 expression was also correlated with several genes encoding glycosylation 407 
enzymes or glycoproteins. This essential set of genes is involved in a wide set of cellular 408 
function including cell adhesion, barrier role, interaction with selection of endothelial cells or 409 
regulation of cell signaling [5, 44]. The glycan-associated antigens are commonly associated 410 
with patient survival of gastrointestinal cancer [45]. Alteration of MUC4 glycosylation is 411 
proposed to play a substantial role in binding properties mediated by the extracellular subunit 412 
of MUC4 and the NIDO domain [46]. One should note that the expression of these genes is 413 
correlated with MUC4. However, a direct regulatory mechanism remains to be demonstrated 414 
in future studies. 415 
In order to regulate these major biological properties, MUC4 has been commonly associated 416 
with cell signaling alteration and notably MAPK, NF-kB, or FAK signaling pathways. 417 
Interestingly, we observed that MUC4 expression is highly correlated with proteins containing 418 
Src Homology 2 (SH2) domain or Src Homology 3 (SH3) domains. Intracellular adaptor 419 
signaling proteins family is characterized by one SH2 and at least one SH3 domain and is 420 
crucial for effective integrating of intracellular and extracellular stimuli [47].  421 
It is interesting to note that MUC4 expression is not correlated with MUC1 that is a major 422 
membrane-bound mucin commonly overexpressed in cancer [48, 49]. In the US, it was 423 
estimated that 900 000 cancers, out of 1 400 000, harbor overexpression of MUC1 424 
highlighting its attractiveness as a therapeutic target. This could be explained by different 425 
regulatory mechanisms such as different signaling pathways or different miRNA regulating 426 
the two mucins.  427 
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MUC16 is the peptide part to the CA125 serum marker for ovarian cancer [50]. MUC16 is a 428 
very large mucin (22 000 amino acid (aa)) that is heavily glycosylated and facilitates ovarian 429 
cancer. MUC20 is a small mucin (500 aa) mostly expressed in renal proximal tube and that is 430 
deregulated in several cancers such as colorectal or ovarian cancers where it favors 431 
aggressiveness [17, 18]. MUC16/CA125 is routinely used in clinics unlike MUC4 and 432 
MUC20. In the present manuscript, we showed that expression of MUC16 and MUC20 are 433 
positively correlated with MUC4 and that the MUC4/MUC16/MUC20high combinatory 434 
expression is associated with an increased hazard ratio and reduced overall survival 435 
suggesting a potential for this signature as a prognostic marker for several carcinomas and 436 
notably pancreatic, stomach and colon cancer. Biomarkers for pancreatic cancer are needed 437 
for detection and evaluation of response to therapy [51]. Unfortunately, the marker currently 438 
used (CA19.9) lacks sensitivity or specificity to be used in cancer diagnosis. Similarly 439 
established biomarker with adequate sensitivity and specificity are lacking for gastric  cancer 440 
[52]. The need of biomarkers is less urgent for colorectal cancer since several 441 
predictive/prognostic/diagnostic biomarkers have been described [53].  442 
The present work highlights the relationship between MUC4/MUC16/MUC20 expression and 443 
overall survival. This signature could be proposed as a prognostic marker. Moreover, MUC4 444 
is expressed in the earliest stage (PanIN1A) of pancreatic cancer but is not specific enough. 445 
The potential of the combination MUC4/MUC16/MUC20 as a diagnosis marker is not known 446 
and remains to be investigated in the future. Moreover, development of unsupervised 447 
algorithm will allow the identification of new non intentional bigger signatures leading to 448 
better prognostic and predictive performances. Genome wide computational unsupervised 449 
procedure from discovery dataset will help to determine hypothesis signature. The signature 450 
will be subsequently validated on a number of independents datasets. Thus, multi-platform 451 
analysis using TCGA datasets helped to characterize the complex molecular landscape of 452 
PDAC [54]. Another meta-analysis approach based on PC datasets allowed the identification 453 
of a 5 genes classifier signature (TMPRSS4, AHNAK2, POSTN, ECT2, SERPINB5) with 454 
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95% sensitivity and 89% specificity in discriminating PDAC from non-tumor samples [55]. 455 
Interestingly, TMPRSS4 and SERPINB5 are two genes belonging to the gene list correlated 456 
with MUC4 expression. 457 
  458 
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Conclusion 459 
 460 
We analyzed MUC4 expression systematically in all organs in TCGA and CCLE large scale 461 
databases and confirmed its aberrant expression in associated carcinoma and the MUC4 462 
impact on patient’s survival. Moreover, 187 genes (involved in cell adhesion, cell-cell 463 
junctions, glycosylation and cell signaling) were correlated with MUC4. Among them, MUC16 464 
and MUC20 membrane bound mucins and their combination MUC4/MUC16/MUC20 is 465 
associated with a poorer overall survival in different cancers including pancreatic, colon and 466 
stomach cancers suggesting MUC4/MUC16/MUC20 as a poor prognostic signature for these 467 
cancers. This potential as new biomarkers remains to be investigated in the future.  468 
 469 
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Figure legends 636 
 637 
Figure 1: Strategy of analysis of genes correlated with MUC4 expression in Cancer 638 
Cell Line Encyclopedia. (A) Flowchart of MUC4 analysis. MUC4 mRNA expression z-639 
scores were extracted from Cancer Cell Line Encyclopedia using cBioportal . The list of gene 640 
correlated with MUC4 expression was determined by using the co-expression tool. Genes 641 
presenting a Pearson’s correlation higher than 0.3 or lower than -0.3 were selected. 642 
Spearman analysis was performed subsequently. Gene ontology annotation and clustering 643 
were performed using DAVID 6.8 functional annotation tool . (B) Example of MUC4-MUC16 644 
correlation of mRNA expression. (C) Example of MUC4-MUC20 correlation of mRNA 645 
expression. 646 
 647 
Figure 2: MUC4 expression in Cancer Cell Line Encyclopedia. MUC4 mRNA expression 648 
z-scores were extracted from Cancer Cell Line Encyclopedia (Novartis/Barretina Nature 649 
2012) using cBioportal . N=881 samples. Expression data were sorted depending on tumor 650 
type (A) and histology (B). 651 
 652 
Figure 3: MUC4 expression in cancer samples from TCGA. MUC4 mRNA expression z-653 
scores were extracted from TCGA samples using cBioportal. N=13 489 samples. Expression 654 
data were sorted depending on organs. 655 
 656 
Figure 4: Correlation of MUC4 expression and methylation of genes correlated with 657 
MUC4. The top genes were defined as genes harboring Pearson’s correlation higher than 658 
0.5 with MUC4 expression. MUC4 mRNA expression and methylation score (Reduced 659 
Representation Bisulfite Sequencing: RRBS) of ADGRF1, LCN2, MUC20, C1ORF116, 660 
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STEAP4, SCEL, WFDC2, GJB3, SH2D3A, RNF39, PRSS22, HS3ST1, GPR87, TACST2, 661 
MUC16, FAM83A, LAMC2, B3GNT3, CLDN7 were extracted using 662 
https://portals.broadinstitute.org/ccle 663 
 664 
Figure 5: MUC4 expression is associated with reduced overall survival of carcinoma. 665 
(A) Hazard ratio was calculated in population designated as MUC4 high risk and low risk 666 
(higher value of MUC4 for higher risk) by SurvExpress optimized algorithm  in every cancer 667 
from TCGA datasets. (B) Overall survival values of MUC4 high and low risk groups in 668 
bladder cancer, colon cancer, lung adenocarcinoma, lung squamous carcinoma, ovarian 669 
cancer, skin cancer, stomach cancer, available in TCGA datasets. The numbers below 670 
horizontal axis represent the number of individuals not presenting the event of MUC4 high 671 
and low risk group along time. 672 
 673 
Figure 6: Hazard ratio of signatures defined by gene ontology terms and top-genes 674 
correlated with MUC4. (A) Hazard ratio was calculated in bladder cancer, colon cancer, 675 
lung adenocarcinoma, lung squamous carcinoma, ovarian cancer, pancreatic cancer, skin 676 
cancer and stomach cancer. The populations were defined according to GO term extracted 677 
from list of gene correlated with MUC4 (GO 0031424: keratinization, GO 0007155: cell 678 
adhesion, GO 0019897: extrinsic component of plasma membrane, GO 0016323 : 679 
basolateral plasma membrane and GO 0016324: apical plasma membrane). (B) A) Hazard 680 
ratio was calculated in populations designated as high risk and low risk for top genes 681 
(ADGRF1, LCN2, MUC20, C1ORF116, SCEL, STEAP4) that harbored Pearson’s correlation 682 
with MUC4 superior to 0.5. 683 
 684 
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Figure 7: MUC4/MUC16/MUC20 expression is associated with reduced overall survival 685 
of pancreatic adenocarcinoma. (A) Overall survival of MUC4/MUC16/MUC20 high and low 686 
risk group in pancreatic cancer available in TCGA datasets. High risk and low risk cohorts 687 
were determined by SurvExpress optimized algorithm. Log rang test and Hazard ratio were 688 
calculated to compare both cohorts. (B) Box plot of MUC4, MUC16 and MUC20 expression 689 
and the corresponding p value testing the differences between high risk and low risk groups. 690 
(C) Overall survival of MUC4/MUC16/MUC20 high and low risk groups in ICGC, Stratford 691 
(GSE21521) and Zhang (GSE 28735) datasets available in SurvExpress. 692 
 693 
Figure 8: Expression and ROC curves of the MUC4/MUC16/MUC20 signature in a 694 
pancreatic adenocarcinoma dataset. (A) MUC4, MUC16 and MUC20 mRNA expression 695 
was evaluated in GSE28735 dataset to analyze whether the mRNA level differed between 696 
normal and tumor tissues. Statistical analyses were performed using paired t-test (**** 697 
p<0.0001, ** p<0.01). (B) ROC curves and Area under ROC measurement (AUROC) of 698 
MUC4, MUC16, MUC20 and the combination in GSE28735 dataset. 699 
 700 
Table 1: List of mRNA positively correlated with MUC4. Data were retrieved from 881 701 
samples of Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012). Correlation 702 
analysis was performed using cBioPortal.org online tool. 178 genes presented a Pearson’s  703 
correlation higher than 0.3. 704 
 705 
Table 2: List of mRNA negatively correlated with MUC4. Data were retrieved from 881 706 
samples of Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012). Correlation 707 
analysis was performed using cBioPortal.org online tool. 9 genes presented a Pearson’s 708 
correlation lower than -0.3. 709 
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 710 
Table 3: Gene ontology clustering on genes correlated with MUC4 expression. Gene 711 
list was retrieved from 881 samples of Cancer Cell Line Encyclopedia (Baretina, Nature 712 
2012). 187 genes that are positively (n=178) or negatively (n=9) correlated with MUC4 713 
expression were selected. Functional Annotation and gene clustering were performed using 714 
David Functional Annotation Tool. 715 
 716 
Table 4: Hazard-ratio and survival analysis of high and low risk in TCGA tumor 717 
databases. Hazard ratio and p-value were determined using SurvExpress tool. Risk group 718 
were determined using the optimization algorithm (maximize) from the ordered prognostic 719 
index (higher values of MUC4 expression for higher risk). 720 
 721 
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Supplemental material legends 723 
 724 
Supplemental Figure 1: MUC4 Oncoprint in Cancer Cell Line Encyclopedia. MUC4 725 
alterations were explored in Cancer Cell Line Encyclopedia dataset using cBioPortal webtool. 726 
The oncoprint represents the amplification, deletion, up regulation or in frame mutation.  727 
 728 
Supplemental Figure 2: MUC4 expression in normal tissues. MUC4 expression was 729 
analyzed with https://gtexportal.org. Expression is shown as log10 of RKPM (read per 730 
kilobases of transcript per million map reads). Boxplot are shown as median and 25/75% 731 
percentile. Outliers are represented as points. 732 
 733 
Supplemental figure 3: interaction network of the proteins correlated with MUC4 734 
expression. Interacting proteins were determined by String 10 tool and are represented by 735 
nodes. Edges represent a relationship between two nodes (known interaction from curated 736 
databases or experimentally determined; predicted interaction from gene neighborhood, gene 737 
fusion or co-occurrence; textmining; co-expression; protein homology). The obtained network 738 
was divided in 3 clusters by k-means clustering. 739 
 740 
Supplemental Figure 4: Correlation of MUC4 expression and copy numbers of genes 741 
correlated with MUC4. The top genes were defined as genes harboring Pearson’s 742 
correlation higher than 0.5 with MUC4 expression. MUC4 mRNA expression and log2 copy 743 
number of ADGRF1, LCN2, MUC20, C1ORF116, STEAP4, SCEL, MUC16 were extracted 744 
using https://portals.broadinstitute.org/ccle 745 
 746 
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Supplemental Figure 5: Overall survival of MUC4/MUC16/MUC20 high and low risk 747 
groups in cancer datasets available in TCGA. (A) Overall survival of 748 
MUC4/MUC16/MUC20 high and low risk groups in bladder cancer, colon cancer, lung 749 
adenocarcinoma, lung squamous adenocarcinoma, skin cancer and stomach cancer. High 750 
risk and low risk cohorts were determined by SurvExpress optimized algorithm. Log rang test 751 
and Hazard ratio were calculated to compare both cohorts. The numbers below horizontal 752 
axis represent the number of individuals not presenting the event of MUC4 high and low risk 753 
group along time. (B) Overall survival of MUC4/MUC16/MUC20 high and low risk group in 754 
liver and acute myeloid leukemia (AML). 755 
 756 
Supplemental Figure 6: MUC4-MUC16 and MUC4-MUC20 correlation of mRNA 757 
expression in 45 tumor tissues of GSE28735 PDAC dataset. 758 
 759 
Supplemental Figure 7: MUC4, MUC16 and MUC20 expression in bladder, colorectal, 760 
lung, stomach, skin and ovarian cancer datasets. MUC4, MUC16 and MUC20 mRNA 761 
expression was evaluated in datasets to analyze whether the mRNA level differed between 762 
normal and tumor tissues. (A) GSE13507 contains 165 bladder cancer and 58 ANT samples. 763 
(B) GSE30219 contains 14 normal lung, 85 adenocarcinomas and 61 squamous cancer 764 
samples. (C) GSE40967 contains 566 colorectal cancers and 19 normal mucosae. (D) 765 
GSE27342 contains 80 tumors and 80 paired ANT tissues. (E) GSE4587 contains 2 normal, 766 
2 melanomas and 2 metastatic melanomas. (F) GSE14407 contains 12 ovarian 767 
adenocarcinomas and 12 normal ovary samples. Statistical analyses were performed using 768 
paired t-test (* p<0.05, ** p<0.01). 769 
 770 
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Supplemental table 1: Ontology of genes correlated with MUC4 expression. Gene list 771 
was retrieved from 881 samples of Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 772 
2012). 187 genes that are positively (n=178) or negatively (n=9) correlated with MUC4 773 
expression were selected. Functional Annotation was performed using David Functional 774 
Annotation Tool. 775 
 776 
Supplemental table 2: Hazard-ratio and survival analysis of most significant genes 777 
clustered in GO term associated with MUC4 expression in TCGA tumor databases. 778 
Hazard ratio and p-value were determined using SurvExpress tool 779 
(http://bioinformatica.mty.itesm.mx/SurvExpress). Risk groups were sorted depending on the 780 
major GO term GO 0031424, GO 00071555, GO 0019897, GO 0016323 and GO 0016324  781 
using the optimization algorithm (maximize) from the ordered prognostic. 782 
 783 
Supplemental table 3: Hazard-ratio and survival analysis of top genes associated with 784 
MUC4 expression in TCGA tumor databases. Hazard ratio and p-value were determined 785 
using SurvExpress tool (http://bioinformatica.mty.itesm.mx/SurvExpress). Risk groups were 786 
defined using the optimization algorithm (maximize) from the ordered prognostic. Selected 787 
genes (ADGRF1, LCN2, MUC20, C1ORF116, SCEL, STEAP4) harbored Pearson’s 788 
correlation with MUC4 > 0.5. 789 
Table 1: List of mRNA positively correlated with MUC4. Data were retrieved from 881 samples of 
Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012). Correlation analysis was performed 
using cBioPortal.org online tool. 178 genes presented a Pearson’s correlation higher than 0.3. 
Correlated gene cytoband Pearson's correlation Spearman's correlation 
ADGRF1 6p12.3 0.56 0.40 
LCN2 9q34 0.54 0.41 
MUC20 3q29 0.54 0.42 
C1ORF116 1q32.1 0.52 0.47 
SCEL 13q22 0.52 0.43 
STEAP4 7q21.12 0.51 0.35 
WFDC2 20q13.12 0.48 0.31 
GJB3 1p34 0.48 0.35 
SH2D3A 19p13.3 0.48 0.45 
RNF39 6p21.3 0.47 0.35 
PRSS22 16p13.3 0.47 0.41 
HS3ST1 4p16 0.46 0.35 
GPR87 3q24 0.46 0.35 
TACSTD2 1p32 0.46 0.41 
MUC16 19p13.2 0.46 0.37 
FAM83A 8q24.13 0.45 0.34 
LAMC2 1q25-q31 0.45 0.32 
B3GNT3 19p13.1 0.45 0.40 
CLDN7 17p13.1 0.45 0.44 
ELF3 1q32.2 0.44 0.44 
MIR205HG 1q32.2 0.44 0.37 
PPL 16p13.3 0.44 0.40 
MPZL2 11q24 0.44 0.43 
TMPRSS4 11q23.3 0.44 0.46 
C6ORF132 6p21.1 0.43 0.36 
FGFBP1 4p15.32 0.43 0.38 
IRF6 1q32.3-
q41 
0.43 0.44 
LAMB3 1q32 0.43 0.31 
CDH3 16q22.1 0.43 0.41 
SPINT1 15q15.1 0.43 0.42 
EHF 11p12 0.43 0.41 
CYSRT1 9q34.3 0.42 0.33 
MACC1 7p21.1 0.42 0.38 
MST1R 3p21.3 0.42 0.41 
SERPINB5 18q21.33 0.42 0.39 
TMEM30B 14q23.1 0.42 0.40 
CLDN4 7q11.23 0.41 0.37 
LIPH 3q27 0.41 0.36 
ALS2CL 3p21.31 0.41 0.37 
ITGB6 2q24.2 0.41 0.37 
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RAB25 1q22 0.41 0.41 
CNKSR1 1p36.11 0.41 0.43 
TSPAN1 1p34.1 0.41 0.36 
CEACAM6 19q13.2 0.41 0.37 
KLK10 19q13 0.41 0.37 
UCA1 19p13.12 0.41 0.32 
CXCL16 17p13 0.41 0.35 
ELMO3 16q22.1 0.41 0.44 
PRSS8 16p11.2 0.41 0.42 
ST14 11q24-
q25 
0.41 0.40 
TRIM29 11q23.3 0.41 0.37 
GRHL2 8q22.3 0.40 0.40 
PTK6 20q13.3 0.40 0.34 
FLJ23867 1q25.2 0.40 0.31 
TMC4 19q13.42 0.40 0.38 
CDH1 16q22.1 0.40 0.39 
SDR16C5 8q12.1 0.39 0.35 
S100A14 1q21.3 0.39 0.38 
GJB5 1p35.1 0.39 0.33 
JUP 17q21 0.39 0.40 
TMC5 16p12.3 0.39 0.42 
SCGB1A1 11q12.3 0.39 0.34 
MROH6 8q24.3 0.38 0.39 
MAL2 8q23 0.38 0.41 
ESRP1 8q22.1 0.38 0.42 
GALNT3 2q24-q31 0.38 0.38 
CBLC 19q13.2 0.38 0.40 
FUT3 19p13.3 0.38 0.42 
PKP3 11p15 0.38 0.39 
EPHA1 7q34 0.37 0.39 
AGR2 7p21.3 0.37 0.33 
CDS1 4q21.23 0.37 0.37 
S100P 4p16 0.37 0.36 
ARL14 3q25.33 0.37 0.33 
KRTCAP3 2p23.3 0.37 0.41 
BIK 22q13.31 0.37 0.38 
SFN 1p36.11 0.37 0.41 
TMEM125 1p34.2 0.37 0.44 
C19ORF33 19q13.2 0.37 0.35 
LSR 19q13.12 0.37 0.41 
MISP 19p13.3 0.37 0.39 
ESRP2 16q22.1 0.37 0.39 
PAK6 15q14 0.37 0.37 
KRT4 12q13.13 0.37 0.32 
ANKRD22 10q23.31 0.37 0.40 
MARVELD2 5q13.2 0.36 0.38 
LAD1 1q25.1-
q32.3 
0.36 0.38 
F11R 1q21.2-
q21.3 
0.36 0.44 
CGN 1q21 0.36 0.42 
ARHGEF16 1p36.3 0.36 0.43 
KIAA1522 1p35.1 0.36 0.33 
DMKN 19q13.12 0.36 0.34 
STAP2 19p13.3 0.36 0.34 
EVPL 17q25.1 0.36 0.38 
ITGB4 17q25 0.36 0.36 
MARVELD3 16q22.2 0.36 0.42 
CCDC64B 16p13.3 0.36 0.38 
KLF5 13q22.1 0.36 0.35 
KRT6A 12q13.13 0.36 0.33 
EXPH5 11q22.3 0.36 0.37 
PLEKHA7 11p15.1 0.36 0.33 
PRRG4 11p13 0.36 0.33 
ADAP1 7p22.3 0.35 0.35 
IL1RN 2q14.2 0.35 0.36 
EPCAM 2p21 0.35 0.38 
PVRL4 1q23.3 0.35 0.31 
EPS8L1 19q13.42 0.35 0.39 
PRRG2 19q13.33 0.35 0.43 
FXYD3 19q13.12 0.35 0.37 
CRB3 19p13.3 0.35 0.40 
MYO5C 15q21 0.35 0.37 
TC2N 14q32.12 0.35 0.38 
PLEKHG3 14q23.3 0.35 0.35 
FAM83H 8q24.3 0.34 0.39 
FRK 6q21-
q22.3 
0.34 0.31 
FAM110C 2p25.3 0.34 0.35 
KDF1 1p36.11 0.34 0.40 
KLK6 19q13.3 0.34 0.38 
SPINT2 19q13.1 0.34 0.39 
TTC9 14q24.2 0.34 0.32 
FOXA1 14q21.1 0.34 0.36 
TJP2 9q13-q21 0.33 0.31 
ARHGEF5 7q35 0.33 0.33 
MAPK13 6p21.31 0.33 0.32 
ZNF165 6p21.3 0.33 0.41 
ANXA3 4q21.21 0.33 0.30 
B3GNT5 3q28 0.33 0.32 
ZBED2 3q13.2 0.33 0.31 
GRHL1 2p25.1 0.33 0.38 
FERMT1 20p12.3 0.33 0.31 
SPRR1A 1q21-q22 0.33 0.31 
S100A9 1q21 0.33 0.33 
PCSK9 1p32.3 0.33 0.34 
CEACAM5 19q13.1-
q13.2 
0.33 0.33 
KLK8 19q13 0.33 0.36 
GNA15 19p13.3 0.33 0.32 
KRT19 17q21.2 0.33 0.32 
TNS4 17q21.2 0.33 0.41 
PLEK2 14q23.3 0.33 0.32 
DTX4 11q12.1 0.33 0.31 
TSPAN15 10q22.1 0.33 0.34 
CHMP4C 8q21.13 0.32 0.38 
DAPP1 4q25-q27 0.32 0.32 
PROM2 2q11.1 0.32 0.37 
AIM1L 1p36.11 0.32 0.42 
GRHL3 1p36.11 0.32 0.34 
MYH14 19q13.33 0.32 0.41 
TJP3 19p13.3 0.32 0.40 
DSC2 18q12.1 0.32 0.32 
LLGL2 17q25.1 0.32 0.40 
IL18 11q23.1 0.32 0.32 
OVOL1 11q13 0.32 0.40 
CORO2A 9q22.3 0.31 0.34 
TMEM184A 7p22.3 0.31 0.40 
MAP7 6q23.3 0.31 0.33 
IL20RA 6q23.3 0.31 0.37 
DDR1 6p21.3 0.31 0.32 
FAM83B 6p12.1 0.31 0.37 
LAMP3 3q26.3-
q27 
0.31 0.36 
OVOL2 20p11.23 0.31 0.41 
KCNK1 1q42-q43 0.31 0.35 
PTAFR 1p35-
p34.3 
0.31 0.34 
FUT2 19q13.3 0.31 0.38 
LRG1 19p13.3 0.31 0.32 
ST6GALNAC1 17q25.1 0.31 0.43 
GRB7 17q12 0.31 0.38 
ATP2C2 16q24.1 0.31 0.42 
PLA2G10 16p13.1-
p12 
0.31 0.39 
SCNN1A 12p13 0.31 0.40 
TMEM45B 11q24.3 0.31 0.38 
EZR 6q25.3 0.30 0.31 
ARAP2 4p14 0.30 0.31 
CDCP1 3p21.31 0.30 0.30 
PTPRU 1p35.3 0.30 0.30 
KLC3 19q13 0.30 0.36 
EPN3 17q21.33 0.30 0.39 
ARHGAP27 17q21.31 0.30 0.35 
FA2H 16q23 0.30 0.40 
 
Table 2: List of mRNA negatively correlated with MUC4. Data were retrieved from 881 samples of 
Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012). Correlation analysis was performed 
using cBioPortal.org online tool. 9 genes presented a Pearson’s correlation lower than -0.3. 
 
Correlated gene cytoband Pearson's correlation Spearman's correlation 
SLC35B4 7q33 -0.30 -0.32 
IFFO1 12p13.3 -0.30 -0.36 
TTC28 22q12.1 -0.31 -0.33 
VKORC1 16p11.2 -0.31 -0.35 
DIXDC1 11q23.1 -0.31 -0.31 
ATP8B2 1q21.3 -0.32 -0.33 
ST3GAL2 16q22.1 -0.32 -0.31 
ZEB1 10p11.2 -0.33 -0.35 
MTFR1L 1p36.11 -0.34 -0.35 
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Table 3: Gene ontology clustering on genes correlated with MUC4 expression. Gene 
list was retrieved from 881 samples of Cancer Cell Line Encyclopedia (Baretina, Nature 
2012). 187 genes that are positively (n=178) or negatively (n=9) correlated with MUC4 
expression were selected. Functional Annotation and gene clustering were performed using 
David Functional Annotation Tool (https://david.ncifcrf.gov/). 
Enrichment 
score 
Gene Ontology terms and annotations 
 
Count P value 
7.08 Cell-cell adherens junction 
cadherin binding involved in cell-cell adhesion 
cell-cell adhesion 
18 
17 
14 
1.4E-8 
2.0E-8 
2.2E-6 
5.44 Tight junction 
bicellular tight junction 
Tight junction 
bicellular tight junction assembly 
10 
10 
9 
5 
6.6E-8 
1.4E-6 
8.1E-6 
2.4E-4 
4.67 Pleckstrin homology-like domain 
Pleckstrin homology domain 
domain:PH 
PH 
17 
13 
11 
12 
2.6E-6 
9.3E-6 
8.0E-5 
1.1E-4 
3.35 SH2 domain 
domain:SH2 
SH2 domain 
SH2 
8 
7 
7 
6 
9.1E-5 
2.3E-4 
3.9E-4 
4.8E-3 
3.34 Glycoprotein 
glycosylation site:N-linked (GlcNAc...) 
disulfide bond 
signal peptide 
Disulfide bond 
Signal 
64 
61 
44 
48 
48 
54 
6.0E-5 
1.1E-4 
6.4E-4 
9.7E-4 
9.8E-4 
2.2E-3 
2.76 topological domain:Cytoplasmic 
Membrane 
transmembrane region 
topological domain:Extracellular 
Transmembrane helix 
Transmembrane 
integral component of membrane 
53 
91 
66 
42 
66 
66 
59 
8.1E-5 
1.6E-4 
8.5E-4 
9.2E-4 
7.2E-3 
7.7E-3 
8.4E-2 
2.6 domain:SH3 
SH3 domain 
Src homology-3 domain 
SH3 
9 
9 
8 
6 
1.9E-4 
6.5E-4 
4.4E-3 
6.9E-2 
2.48 signal peptide 
Secreted 
extracellular region 
48 
31 
25 
9.7E-4 
2.0E-3 
1.9E-2 
2.43 establishment of protein localization to plasma 
membrane 
cell adhesion molecule binding 
actin cytoskeleton 
6 
5 
4 
4.9E-5 
3.0E-3 
3.5E-1 
2.32 extracellular matrix organization 
Epidermolysis bullosa, junctional, non-Herlitz type 
Epidermolysis bullosa 
hemidesmosome assembly 
10 
3 
4 
3 
1.2E-4 
2.8E-4 
2.8E-4 
5.7E-3 
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ECM-receptor interaction 
Focal adhesion 
PI3K-Akt signaling pathway 
4 
5 
4 
2.9E-2 
7.2E-2 
5.0E-1 
2.19 Serine protease 
Peptidase S1, trypsin family, active site 
domain:Peptidase S1 
active site:Charge relay system 
Peptidase S1 
Trypsin-like cysteine/serine peptidase domain 
Tryp_SPc 
extrinsic component of plasma membrane 
Peptidase S1A, chymotrypsin-type 
serine-type endopeptidase activity 
serine-type peptidase activity 
Protease 
Zymogen 
proteolysis 
Hydrolase 
8 
7 
7 
9 
7 
7 
7 
4 
6 
8 
4 
8 
4 
7 
13 
2.5E-4 
3.9E-4 
4.7E-4 
5.3E-4 
9.1E-4 
1.3E-3 
1.6E-3 
1.7E-3 
4.1E-3 
1.2E-2 
2.3E-2 
2.0E-1 
2.9E-1 
3.5E-1 
8.1E-1 
1.74 CP2 transcription factor 
region of interest:Transcription activation 
chromatin DNA binding 
sequence-specific DNA binding 
3 
3 
3 
8 
1.3E-3 
3.5E-3 
1.1E-1 
2.3E-1 
1.69 O-glycan processing 
Glycosphingolipid biosynthesis - lacto and neolacto 
series 
protein glycosylation 
Glycosyltransferase 
topological domain:Lumenal 
Golgi cisterna membrane 
Signal-anchor 
Golgi apparatus 
Golgi membrane 
Metabolic pathways 
6 
4 
 
6 
7 
10 
4 
9 
12 
9 
9 
2.7E-4 
9.8E-4 
 
4.7E-3 
1.8E-2 
2.1E-2 
3.6E-2 
4.8E-2 
1.0E-1 
2.0E-1 
7.5E-1 
1.51 Rho guanyl-nucleotide exchange factor activity 
regulation of Rho protein signal transduction 
Dbl homology (DH) domain 
domain:DH 
RhoGEF 
5 
5 
4 
3 
3 
6.4E-3 
7.6E-3 
2.9E-2 
1.3E-1 
1.6E-1 
 
Table 4: Hazard-ratio and survival analysis of high and low risk in TCGA tumor 
databases. Hazard ratio and p-value were determined using SurvExpress tool 
(http://bioinformatica.mty.itesm.mx/SurvExpress). Risk groups were determined using the 
optimization algorithm (maximize) from the ordered prognostic index (higher values of MUC4 
expression for higher risk).  
Database N; low vs 
risk group 
Hazard ratio 
[95% CI] 
P value 
Bladder − BLCA−TCGA−Bladder 
Urothelial Carcinoma−July 2016 
N=388; 251 
vs 137 
1.48 [1.09 ; 2] p=0.01191 
Breast − BRCA−TCGA Breast invasive 
carcinoma − July 2016 
N=962; 831 
vs 131 
1.06 [0.67 ; 
1.67] 
p=0.8038 
Cervical − CESC−TCGA Cervical 
squamous cell carcinoma and 
endocervical adenocarcinoma July 2016 
N=191; 147 
vs 44 
1.55 [0.76  
 ; 3.17] 
p=0.2275 
Colon − COADREAD − TCGA Colon and 
Rectum adenocarcinoma June 2016 
N=466;  417 
vs 49 
2.1 [1.19 ; 3.71] p=0.01061 
Esophagus − ESCA −  TCGA Esophageal 
carcinoma June 2016 
N=184; 137 
vs 47 
0.68 [0.4 ; 1.15] p=0.1468 
Head−Neck − HNSC − TCGA Head and 
Neck squamous cell carcinoma June 2016 
N=502; 107 
vs 395 
1.26 [0.88 ; 
1.78] 
p=0.204 
Hematologic − Acute Myeloid Leukemia 
TCGA 
N=168; 146 
vs 22 
1.59 [0.97 ; 
2.62],  
p=0.06818 
Kidney − KIPAN − TCGA Kidney PAN 
cancer TCGA June 2016 
N=792; 555 
vs 237 
0.94 [0.7 ; 1.26] p=0.6711 
Kidney − KIRC − TCGA − Kidney renal 
clear cell carcinoma 
N=415; 256 
vs 159 
0.98 [0.7 ; 1.37] p=0.9115 
Kidney − KIRP − TCGA Kidney renal 
papillary cell carcinoma June 2016 
N=278; 248 
vs 30 
1.24 [0.52 ; 
2.94] 
p=0.6322 
Liver − TCGA−Liver−Cancer N=304; 137 
vs 167 
1.4 [0.97 ; 2.03] p=0.07012 
Lung ADK− LUAD − TCGA − Lung 
adenocarcinoma June 2016 
N=475; 410 
vs 65 
1.7 [1.14 ; 2.52] p=0.008963 
Lung Squamous− LUSC − TCGA − Lung 
squamous cell carcinoma June 2016 
N=175; 59 
vs 116 
1.69 [1.03 ; 
2.78],  
p=0.03798 
Ovarian − Ovarian serous 
cystadenocarcinoma TCGA 
N=578; 390 
vs 188 
1.33 [1.05 ; 
1.69] 
p=0.01908 
Pancreatic − PAAD − TCGA − Pancreatic 
adenocarcinoma 
N=176; 27 
vs 149 
3.94 [1.81 ; 
8.61] 
p=0.0005756 
Prostate − PRAD − TCGA − Prostate 
adenocarcinoma June 2016 
N=497; 328 
vs 169 
1.99 [0.57 ; 
6.88],  
p=0.2793 
Skin − SKCM−TCGA Skin Cutaneous 
Melanoma July 2016 
N=334; 312 
vs 23 
1.87 [1.08 ; 
3.23]  
p=0.0262 
Stomach − STAD − TCGA − Stomach 
adenocarcinoma June 2016 
N=352; 306 
vs 46 
1.58 [1 ; 2.51],  p=0.04958 
Testis − TGCT − TCGA − Testicular Germ 
Cell Tumors 
N=133; 93 
vs 40 
5.56 [0.57 ; 
54.52] 
p=0.1407 
Thymus − THYM − TCGA − Thymoma 
June 2016 
N=118; 90 
vs 28 
1.92 [0.48 ; 
7.77] 
P=0.3588 
Thyroid − THCA − TCGA − Thyroid 
carcinoma − June 2016 
N=247; 45 
vs 202 
1.98 [0.69 ; 
5.64],  
p=0.2019 
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DAVID6.8 Functional Annotation Tool
cBioPortal.org: Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012)
n=881 samples
Query: MUC4
List of genes correlated with MUC4 expression
n=178 positively regulated, table 1
n=9 negatively regulated, table 2
Gene ontology annotation
suppl. table 1
Gene ontology  clustering
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